Drug: |
||||
---|---|---|---|---|
Trial Name: |
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 04/15/2011 |
Age of Trial (yrs) 13 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT + Block blood vessel growth |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
14814 |
|||
Sponsor: |
Bayer |
|||
Patient Contact: |
Bayer Clinical Trials Contact:
clinical-trials-contact@bayerhealthcare.com
888-842-2937 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
BAY 73-4506 is a multi-targeted kinase inhibitor that blocks tumor growth through multiple targets (i.e. Raf-1, BRAF, VEGFR 2/3, c-kit, PDGFR, and FGFR-1). |
Trial Links |
Trial Results |
Name |
Address |
City |
State |
Zip |
Country |
1665 N. Ursula St. |
Aurora |
CO |
80045 |
USA |
|
1500 East Medical Center Dr |
Ann Arbor |
MI |
48109 |
USA |
|
660 S. Euclid Ave |
St. Louis |
MO |
63110 |
USA |
|
Oklahoma City |
OK |
73104 |
USA |
||
3322 West End Avenue |
Nashville |
TN |
37203 |
USA |
|
Seattle |
WA |
98104 |
USA |